IGFDES

IGF-1 DES

No registered human study names IGF-1 DES as an intervention. ClinicalTrials.gov holds no trial of it, so there is no trial evidence to read — a fact about the public record rather than proof the compound does nothing. No FDA-approved product contains IGF-1 DES. No paper naming IGF-1 DES was published in the last ten years.

Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names IGF-1 DES; the registry search is fuzzy, so every match is re-checked. None of this says whether IGF-1 DES works or is safe.

FDA status

Research only

Human studies

0

Furthest phase

Papers, 10 yr

0

Readership

Tracking since 2026-07-29 · About this data

What has actually been tested in humans

X

No registered human study

0

Registered human studies

None

No FDA-approved product contains it

No study of IGF-1 DES in humans is registered on ClinicalTrials.gov. That is a fact about the public record, not a statement that the compound does nothing — but it does mean there is no trial evidence to read, and anyone telling you otherwise should be asked for the registration number. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.

Is anyone studying IGF-1 DES?

No paper naming “IGF-1 DES” in its title or abstract was published between 2017 and 2026, and no registered trial started in that window. That is a fact about the scientific record, not proof the compound does nothing — but it does mean there is no recent literature to read.

Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02 · check the query.

Published research on IGF-1 DES

The 6 papers PubMed ranks most relevant for IGF-1 DES. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.

  1. The effects of insulin-like growth factor (IGF)-1, IGF-2, and des-IGF-1 on neuronal loss after hypoxic-ischemic brain injury in adult rats: evidence for a role for IGF binding proteins

    Guan J, Williams CE, Skinner SJ, et al.Endocrinology1996

    PMID 860360010.1210/endo.137.3.8603600

  2. Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis

    Kaplan-Lefko PJ, Sutherland BW, Evangelou AI, et al.Oncogene2008

    PMID 1802613410.1038/sj.onc.1210943

  3. A key functional role for the insulin-like growth factor 1 N-terminal pentapeptide

    Bagley CJ, May BL, Szabo L, et al.The Biochemical journal1989

    PMID 273058010.1042/bj2590665

  4. Effects of insulin-like growth factors on protein metabolism: why are some molecular variants more potent?

    Ballard FJ, Francis GL, Bagley CJ, et al.Biochemical Society symposium1989

    PMID 2559737

  5. IGF-I has a dual effect on insulin release from isolated, perifused adult rat islets of Langerhans

    Hill DJ, Sedran RJ, Brenner SL, et al.The Journal of endocrinology1997

    PMID 913556510.1677/joe.0.1530015

  6. The direct in vitro effect of insulin-like growth factors (IGFs) on normal bovine mammary cell proliferation and production of IGF binding proteins

    McGrath MF, Collier RJ, Clemmons DR, et al.Endocrinology1991

    PMID 171316010.1210/endo-129-2-671

Collected 2026-08-02from PubMed, phrase-matched on “IGF-1 DES” in title and abstract. Run the same search.

Reading on this compound

All articles

PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.

Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.